Chromosome 18p Deletion Syndrome

Mendelian MONDO:0007800 Pathograph 24 Show in embeddings browser hereditary disease chromosomal disorder

Chromosome 18p deletion syndrome (monosomy 18p) is a contiguous-gene chromosomal disorder caused by deletion of all or part of the short arm of chromosome 18, usually arising de novo as a terminal deletion. First described in 1963, it is one of the most common autosomal terminal-deletion syndromes. Haploinsufficiency of multiple dosage-sensitive genes produces a highly variable phenotype: intellectual disability, postnatal growth retardation and short stature, craniofacial dysmorphism (ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, low-set ears), and a holoprosencephaly spectrum linked to TGIF1 haploinsufficiency. Additional low-penetrance, gene-specific manifestations include GNAL-related dystonia, isolated growth-hormone deficiency / hypopituitarism, IgA / immunoglobulin deficiency, and a conditional risk of facioscapulohumeral muscular dystrophy type 2 (FSHD2) via SMCHD1 hemizygosity. Genotype-phenotype correlation depends on the deletion breakpoint and size.

Ask OpenScientist

Ask a research question about Chromosome 18p Deletion Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
13
Phenotypes
24
Pathograph
3
Genes
6
Medical Actions
1
References
1
Deep Research
👪

Inheritance

1
De novo terminal deletion
Most cases arise from a de novo terminal deletion of the short arm of chromosome 18, with the remaining alleles typically a normal karyotype in the parents. A minority arise from unbalanced translocations or familial transmission.
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The aims of present study were to clinically and molecularly characterize the syndrome further in seven subjects with de novo 18p deletions and to perform genotype-phenotype correlation. All seven subjects had terminal deletions and no interstitial deletion was observed with subtelomeric FISH analyses."
Supports the predominant de novo terminal-deletion mechanism of monosomy 18p.
⚙

Pathophysiology

8
18p haploinsufficiency
Terminal or interstitial deletion of the short arm of chromosome 18 removes one copy of multiple dosage-sensitive genes, producing a contiguous-gene haploinsufficiency syndrome. The extent of the deleted region and which dosage-sensitive genes are rendered hemizygous determine the phenotypic spectrum, including a critical region for intellectual disability and the distal location of genes (e.g., TGIF1) underlying midline brain defects and growth-hormone deficiency.
neural cell CL:0002319
Downstream
TGIF1-dependent midline forebrain patterning defect Hemizygosity of TGIF1 (distal 18p) reduces dosage of a key NODAL/TGF-beta pathway repressor required for ventral forebrain and midline development.
Neurodevelopmental dysregulation Loss of one copy of dosage-sensitive neurodevelopmental genes across 18p impairs cognitive and motor development.
Pituitary and growth dysregulation Distal 18p hemizygosity is associated with isolated growth-hormone deficiency and hypopituitarism, contributing to postnatal growth failure.
Craniofacial dysmorphogenesis Reduced dosage of 18p developmental genes perturbs craniofacial and periocular morphogenesis, producing the characteristic facial gestalt.
GNAL-related basal ganglia dysfunction Hemizygosity of GNAL (encoding G-alpha-olf) confers a low-penetrance risk of dystonia through impaired striatal G-protein signaling.
SMCHD1-dependent epigenetic derepression Hemizygosity of SMCHD1 reduces D4Z4 methylation capacity, conferring a conditional risk of FSHD2 on a permissive chromosome 4q background.
Immune dysregulation 18p hemizygosity is associated with immunoglobulin (IgA/IgG/IgM) deficiency and predisposition to infection and autoimmunity.
Show evidence (2 references)
PMID:16691587 SUPPORT Human Clinical
"The deletion 18p syndrome is one of the most common chromosome abnormalities. The medical problems are mental and postnatal growth retardation, and sometimes malformations of the heart and brain."
Establishes 18p deletion as the initiating lesion producing mental and growth retardation and structural malformations.
PMID:16691587 SUPPORT Human Clinical
"Genotype-phenotype correlation of the seven subjects suggests a correlation between the extent of the deleted region and the mental development."
Supports that haploinsufficiency burden (deletion extent) drives the neurocognitive phenotype, the basis for a contiguous-gene mechanism.
TGIF1-dependent midline forebrain patterning defect
TGIF1 (at distal 18p11.3) encodes a homeodomain transcriptional regulator in the TGF-beta / NODAL signaling pathway that is critical for dorsal-ventral patterning and midline development during embryogenesis. Haploinsufficiency is an established genomic mechanism for holoprosencephaly (HPE) and HPE microforms, with incomplete penetrance; in 18p deletion carriers other genetic or environmental factors modulate expressivity.
neural cell CL:0002319
TGIF1 hgnc:11776
nodal signaling pathway GO:0038092 ⚠ ABNORMAL forebrain development GO:0030900 ⚠ ABNORMAL
Downstream
Holoprosencephaly Disrupted NODAL/TGF-beta-dependent midline forebrain patterning produces holoprosencephaly and its microforms (e.g., single central incisor).
Show evidence (2 references)
PMID:17786116 SUPPORT Human Clinical
"The phenotype of monosomy 18p varies widely, the main clinical manifestations being mental and growth retardation, and craniofacial dysmorphism. Clinical features also include growth hormone (GH) deficiency, or holoprosencephaly (HPE)."
Links monosomy 18p to holoprosencephaly and GH deficiency within the midline-defect spectrum.
PMID:17786116 PARTIAL Human Clinical
"Haploinsufficiency for TGIF, mapped to 18p11.3, is not generally sufficient to cause HPE."
Supports TGIF1 hemizygosity as the candidate HPE mechanism while noting its incomplete penetrance, consistent with the modifier-dependent model.
Neurodevelopmental dysregulation
Hemizygosity of dosage-sensitive 18p genes impairs brain development, producing intellectual disability and global developmental delay. A critical region for intellectual disability lies between 18p11.1 and 18p11.21, and deletion extent correlates with cognitive outcome.
neuron CL:0000540
nervous system development GO:0007399 ⚠ ABNORMAL
Downstream
Intellectual disability Persistent neurodevelopmental disruption manifests as intellectual disability.
Global developmental delay Developmental neurobiologic disruption presents as global developmental delay in infancy and childhood.
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"There might be a critical region for the mental retardation located between 18p11.1 and 18p11.21."
Supports a dosage-dependent critical region underlying the intellectual disability phenotype.
Pituitary and growth dysregulation
Distal 18p hemizygosity is associated with isolated growth-hormone deficiency and, less commonly, hypopituitarism, contributing to postnatal growth retardation and short stature. The distal 18p region is implicated in the GH-deficiency phenotype.
growth hormone secretion GO:0030252 ↓ DECREASED
Downstream
Short stature Growth-hormone deficiency and impaired postnatal growth produce short stature.
Growth hormone deficiency Reduced somatotrope output presents as biochemical growth-hormone deficiency.
Show evidence (1 reference)
PMID:17786116 SUPPORT Human Clinical
"These findings suggest that the distal region on 18p is involved in the main clinical features, and GH deficiency, in 18p deletions."
Maps the GH-deficiency phenotype to distal 18p hemizygosity.
Craniofacial dysmorphogenesis
Reduced dosage of 18p developmental genes perturbs craniofacial and periocular morphogenesis, producing a recognizable but subtle facial gestalt with ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, and large low-set ears.
Downstream
Ptosis Periocular developmental dysregulation presents as ptosis.
Strabismus Ophthalmologic developmental dysregulation presents as strabismus.
Hypertelorism Midface developmental dysregulation presents as hypertelorism.
Micrognathia Mandibular developmental dysregulation presents as micrognathia.
Wide nasal bridge Nasal developmental dysregulation produces a broad, flat nasal bridge.
Low-set ears Auricular developmental dysregulation presents as large, low-set ears.
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The individuals have some typical features, which might be easy to overlook and which are: ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, big and low set ears."
Enumerates the characteristic craniofacial dysmorphic features of the syndrome.
SMCHD1-dependent epigenetic derepression
SMCHD1 (at 18p11.32) is a chromatin modifier that maintains heavy methylation of the D4Z4 macrosatellite repeat on chromosome 4q35, repressing the DUX4 retrogene. In 18p deletion carriers, SMCHD1 hemizygosity combined with a permissive (moderately sized) D4Z4 allele on chromosome 4 can cause facioscapulohumeral muscular dystrophy type 2 (FSHD2) through digenic inheritance, DUX4 derepression, and muscle degeneration.
SMCHD1 hgnc:29090
Show evidence (1 reference)
PMID:29563141 SUPPORT Human Clinical
"Digenic inheritance of a SMCHD1 mutation and a moderately sized D4Z4 repeat on a facioscapulohumeral muscular dystrophy (FSHD) permissive genetic background of chromosome 4 can cause FSHD type 2 (FSHD2)."
Supports SMCHD1 hemizygosity from 18p deletion as a conditional digenic risk factor for FSHD2.
Immune dysregulation
18p hemizygosity is associated with immunoglobulin deficiency (most notably IgA, but also IgG and IgM), predisposing to recurrent infection and autoimmunity.
B cell CL:0000236
Downstream
IgA deficiency Impaired immunoglobulin production presents most commonly as IgA deficiency.
Show evidence (1 reference)
PMID:20635794 SUPPORT Human Clinical
"Immunoglobulin (Ig) A deficiency has long been recognized in patients with chromosome 18 abnormalities."
Documents IgA deficiency as a recognized immune manifestation of chromosome 18 abnormalities, including 18p deletion syndrome.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Chromosome 18p Deletion Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Blood 1
IgA deficiency Decreased circulating IgA concentration HP:0002720
Show evidence (1 reference)
PMID:20635794 SUPPORT Human Clinical
"The association of specific polysaccharide antibody deficiency, IgA deficiency, and chromosome 18p deletion syndrome has not been described previously, and extends the immunological phenotype of antibody deficiencies associated with defects of chromosome 18."
Documents IgA deficiency directly in a patient with chromosome 18p deletion syndrome.
Ear 1
Low-set ears Low-set ears HP:0000369
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The individuals have some typical features, which might be easy to overlook and which are: ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, big and low set ears."
Lists big, low-set ears among the characteristic features of the syndrome.
Eye 3
Ptosis Ptosis HP:0000508
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The individuals have some typical features, which might be easy to overlook and which are: ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, big and low set ears."
Lists ptosis among the characteristic features of the syndrome.
Strabismus Strabismus HP:0000486
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The individuals have some typical features, which might be easy to overlook and which are: ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, big and low set ears."
Lists strabismus among the characteristic features of the syndrome.
Hypertelorism Hypertelorism HP:0000316
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The individuals have some typical features, which might be easy to overlook and which are: ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, big and low set ears."
Lists hypertelorism among the characteristic features of the syndrome.
Head and Neck 1
Micrognathia Micrognathia HP:0000347
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The individuals have some typical features, which might be easy to overlook and which are: ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, big and low set ears."
Lists micrognathia among the characteristic features of the syndrome.
Nervous System 4
Intellectual disability Intellectual disability HP:0001249
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"All the four children with a deletion in the centromeric region at 18p11.1 had a mental retardation (MR)."
Documents intellectual disability (historical term "mental retardation") in 18p deletion patients.
Global developmental delay Global developmental delay HP:0001263
Show evidence (1 reference)
PMID:39058883 SUPPORT Human Clinical
"Chromosome 18p deletion syndrome is caused by total or partial deletion of the short arm of chromosome 18 and associated with cognitive impairment, growth retardation and mild facial dysmorphism."
Supports cognitive impairment / developmental delay as a defining feature.
Holoprosencephaly Holoprosencephaly HP:0001360
Show evidence (1 reference)
PMID:39058883 SUPPORT Human Clinical
"Increased nuchal translucency and holoprosencephaly are common prenatal phenotypes of distal 18p deletion."
Documents holoprosencephaly as a prenatal phenotype of distal 18p deletion.
Dystonia Dystonia HP:0001332
Show evidence (1 reference)
PMID:38258373 SUPPORT Human Clinical
"A Case of 18p Chromosomal Deletion Encompassing GNAL in a Patient With Dystonia-Parkinsonism."
Reports dystonia in an 18p deletion patient with GNAL involvement.
Growth 1
Short stature Short stature HP:0004322
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The medical problems are mental and postnatal growth retardation, and sometimes malformations of the heart and brain."
Documents postnatal growth retardation, the basis for short stature.
Other 2
Growth hormone deficiency Decreased response to growth hormone stimulation test HP:0000824
Show evidence (1 reference)
PMID:17786116 SUPPORT Human Clinical
"Two unrelated children, a 7-month-old girl and a 2-month-old boy had del(18p) syndrome and GH deficiency."
Documents growth-hormone deficiency in del(18p) patients.
Wide nasal bridge Wide nasal bridge HP:0000431
Show evidence (1 reference)
PMID:16691587 SUPPORT Human Clinical
"The individuals have some typical features, which might be easy to overlook and which are: ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, big and low set ears."
Lists a broad flat nose among the characteristic features of the syndrome.
🧬

Genetic Associations

3
TGIF1 haploinsufficiency
Gene: TGIF1 hgnc:11776
Show evidence (1 reference)
PMID:17786116 SUPPORT Human Clinical
"Haploinsufficiency for TGIF, mapped to 18p11.3, is not generally sufficient to cause HPE."
Identifies TGIF1 (18p11.3) haploinsufficiency as the candidate mechanism for holoprosencephaly in monosomy 18p, with incomplete penetrance.
GNAL haploinsufficiency
Gene: GNAL hgnc:4388
Show evidence (1 reference)
PMID:38258373 SUPPORT Human Clinical
"A Case of 18p Chromosomal Deletion Encompassing GNAL in a Patient With Dystonia-Parkinsonism."
Documents GNAL involvement in an 18p deletion patient with dystonia.
SMCHD1 haploinsufficiency
Gene: SMCHD1 hgnc:29090
Show evidence (1 reference)
PMID:29563141 SUPPORT Human Clinical
"Among other genes, structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) is hemizygous in most patients with 18p deletions."
Documents SMCHD1 hemizygosity in most 18p deletion patients, the basis for conditional FSHD2 risk.
💊

Medical Actions

6
Developmental and Behavioral Therapy
Action: occupational therapy MAXO:0001351
Early intervention with developmental, occupational, and behavioral therapy for global developmental delay and intellectual disability.
Speech Therapy
Action: speech therapy MAXO:0000930
Speech-language therapy for expressive language delay, common in 18p deletion syndrome.
Physical Therapy
Action: Physical Therapy NCIT:C15302
Physical therapy for hypotonia and motor delay.
Growth Hormone Replacement Therapy
Action: hormone modifying therapy MAXO:0000283
Agent: somatropin NCIT:C837
Recombinant growth-hormone (somatropin) replacement for documented growth- hormone deficiency, a treatable endocrine manifestation when recognized.
Genetic Counseling
Action: Genetic Counseling NCIT:C15240
Genetic counseling regarding the de novo nature of most cases, recurrence risk, and genotype-specific anticipatory guidance based on deletion breakpoint.
Multidisciplinary Surveillance
Action: supportive care MAXO:0000950
Supportive, multidisciplinary surveillance including endocrine evaluation (growth-hormone testing), immunoglobulin levels, brain MRI, and ophthalmologic examination, individualized by deletion extent.
{ }

Source YAML

click to show 
name: Chromosome 18p Deletion Syndrome
creation_date: "2026-06-22T00:00:00Z"
synonyms:
- Monosomy 18p
- 18p deletion syndrome
- 18p- syndrome
- del(18p)
description: >-
  Chromosome 18p deletion syndrome (monosomy 18p) is a contiguous-gene
  chromosomal disorder caused by deletion of all or part of the short arm of
  chromosome 18, usually arising de novo as a terminal deletion. First described
  in 1963, it is one of the most common autosomal terminal-deletion syndromes.
  Haploinsufficiency of multiple dosage-sensitive genes produces a highly
  variable phenotype: intellectual disability, postnatal growth retardation and
  short stature, craniofacial dysmorphism (ptosis, strabismus, hypertelorism,
  broad flat nose, micrognathia, low-set ears), and a holoprosencephaly spectrum
  linked to TGIF1 haploinsufficiency. Additional low-penetrance, gene-specific
  manifestations include GNAL-related dystonia, isolated growth-hormone
  deficiency / hypopituitarism, IgA / immunoglobulin deficiency, and a
  conditional risk of facioscapulohumeral muscular dystrophy type 2 (FSHD2) via
  SMCHD1 hemizygosity. Genotype-phenotype correlation depends on the deletion
  breakpoint and size.
category: Mendelian
parents:
- hereditary disease
- chromosomal disorder
disease_term:
  preferred_term: chromosome 18p deletion syndrome
  term:
    id: MONDO:0007800
    label: chromosome 18p deletion syndrome
references:
- reference: PMID:26250845
  title: "A review of 18p deletions."
inheritance:
- name: De novo terminal deletion
  description: >-
    Most cases arise from a de novo terminal deletion of the short arm of
    chromosome 18, with the remaining alleles typically a normal karyotype in
    the parents. A minority arise from unbalanced translocations or familial
    transmission.
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aims of present study were to clinically and molecularly characterize
      the syndrome further in seven subjects with de novo 18p deletions and to
      perform genotype-phenotype correlation. All seven subjects had terminal
      deletions and no interstitial deletion was observed with subtelomeric FISH
      analyses.
    explanation: >-
      Supports the predominant de novo terminal-deletion mechanism of monosomy
      18p.
pathophysiology:
- name: 18p haploinsufficiency
  description: >-
    Terminal or interstitial deletion of the short arm of chromosome 18 removes
    one copy of multiple dosage-sensitive genes, producing a contiguous-gene
    haploinsufficiency syndrome. The extent of the deleted region and which
    dosage-sensitive genes are rendered hemizygous determine the phenotypic
    spectrum, including a critical region for intellectual disability and the
    distal location of genes (e.g., TGIF1) underlying midline brain defects and
    growth-hormone deficiency.
  cell_types:
  - preferred_term: neural cell
    term:
      id: CL:0002319
      label: neural cell
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The deletion 18p syndrome is one of the most common chromosome
      abnormalities. The medical problems are mental and postnatal growth
      retardation, and sometimes malformations of the heart and brain.
    explanation: >-
      Establishes 18p deletion as the initiating lesion producing mental and
      growth retardation and structural malformations.
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genotype-phenotype correlation of the seven subjects suggests a
      correlation between the extent of the deleted region and the mental
      development.
    explanation: >-
      Supports that haploinsufficiency burden (deletion extent) drives the
      neurocognitive phenotype, the basis for a contiguous-gene mechanism.
  downstream:
  - target: TGIF1-dependent midline forebrain patterning defect
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Hemizygosity of TGIF1 (distal 18p) reduces dosage of a key NODAL/TGF-beta
      pathway repressor required for ventral forebrain and midline development.
  - target: Neurodevelopmental dysregulation
    description: >-
      Loss of one copy of dosage-sensitive neurodevelopmental genes across 18p
      impairs cognitive and motor development.
  - target: Pituitary and growth dysregulation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Distal 18p hemizygosity is associated with isolated growth-hormone
      deficiency and hypopituitarism, contributing to postnatal growth failure.
  - target: Craniofacial dysmorphogenesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reduced dosage of 18p developmental genes perturbs craniofacial and
      periocular morphogenesis, producing the characteristic facial gestalt.
  - target: GNAL-related basal ganglia dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Hemizygosity of GNAL (encoding G-alpha-olf) confers a low-penetrance risk
      of dystonia through impaired striatal G-protein signaling.
  - target: SMCHD1-dependent epigenetic derepression
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Hemizygosity of SMCHD1 reduces D4Z4 methylation capacity, conferring a
      conditional risk of FSHD2 on a permissive chromosome 4q background.
  - target: Immune dysregulation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      18p hemizygosity is associated with immunoglobulin (IgA/IgG/IgM)
      deficiency and predisposition to infection and autoimmunity.
- name: TGIF1-dependent midline forebrain patterning defect
  description: >-
    TGIF1 (at distal 18p11.3) encodes a homeodomain transcriptional regulator in
    the TGF-beta / NODAL signaling pathway that is critical for dorsal-ventral
    patterning and midline development during embryogenesis. Haploinsufficiency
    is an established genomic mechanism for holoprosencephaly (HPE) and HPE
    microforms, with incomplete penetrance; in 18p deletion carriers other
    genetic or environmental factors modulate expressivity.
  genes:
  - preferred_term: TGIF1
    term:
      id: hgnc:11776
      label: TGIF1
  cell_types:
  - preferred_term: neural cell
    term:
      id: CL:0002319
      label: neural cell
  biological_processes:
  - preferred_term: nodal signaling pathway
    modifier: ABNORMAL
    term:
      id: GO:0038092
      label: nodal signaling pathway
  - preferred_term: forebrain development
    modifier: ABNORMAL
    term:
      id: GO:0030900
      label: forebrain development
  evidence:
  - reference: PMID:17786116
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The phenotype of monosomy 18p varies widely, the main clinical
      manifestations being mental and growth retardation, and craniofacial
      dysmorphism. Clinical features also include growth hormone (GH)
      deficiency, or holoprosencephaly (HPE).
    explanation: >-
      Links monosomy 18p to holoprosencephaly and GH deficiency within the
      midline-defect spectrum.
  - reference: PMID:17786116
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Haploinsufficiency for TGIF, mapped to 18p11.3, is not generally
      sufficient to cause HPE.
    explanation: >-
      Supports TGIF1 hemizygosity as the candidate HPE mechanism while noting
      its incomplete penetrance, consistent with the modifier-dependent model.
  downstream:
  - target: Holoprosencephaly
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Disrupted NODAL/TGF-beta-dependent midline forebrain patterning produces
      holoprosencephaly and its microforms (e.g., single central incisor).
- name: Neurodevelopmental dysregulation
  description: >-
    Hemizygosity of dosage-sensitive 18p genes impairs brain development,
    producing intellectual disability and global developmental delay. A critical
    region for intellectual disability lies between 18p11.1 and 18p11.21, and
    deletion extent correlates with cognitive outcome.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: nervous system development
    modifier: ABNORMAL
    term:
      id: GO:0007399
      label: nervous system development
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There might be a critical region for the mental retardation located
      between 18p11.1 and 18p11.21.
    explanation: >-
      Supports a dosage-dependent critical region underlying the intellectual
      disability phenotype.
  downstream:
  - target: Intellectual disability
    description: >-
      Persistent neurodevelopmental disruption manifests as intellectual
      disability.
  - target: Global developmental delay
    description: >-
      Developmental neurobiologic disruption presents as global developmental
      delay in infancy and childhood.
- name: Pituitary and growth dysregulation
  description: >-
    Distal 18p hemizygosity is associated with isolated growth-hormone
    deficiency and, less commonly, hypopituitarism, contributing to postnatal
    growth retardation and short stature. The distal 18p region is implicated in
    the GH-deficiency phenotype.
  biological_processes:
  - preferred_term: growth hormone secretion
    modifier: DECREASED
    term:
      id: GO:0030252
      label: growth hormone secretion
  evidence:
  - reference: PMID:17786116
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings suggest that the distal region on 18p is involved in the
      main clinical features, and GH deficiency, in 18p deletions.
    explanation: >-
      Maps the GH-deficiency phenotype to distal 18p hemizygosity.
  downstream:
  - target: Short stature
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Growth-hormone deficiency and impaired postnatal growth produce short
      stature.
  - target: Growth hormone deficiency
    description: >-
      Reduced somatotrope output presents as biochemical growth-hormone
      deficiency.
- name: Craniofacial dysmorphogenesis
  description: >-
    Reduced dosage of 18p developmental genes perturbs craniofacial and
    periocular morphogenesis, producing a recognizable but subtle facial gestalt
    with ptosis, strabismus, hypertelorism, broad flat nose, micrognathia, and
    large low-set ears.
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The individuals have some typical features, which might be easy to
      overlook and which are: ptosis, strabismus, hypertelorism, broad flat
      nose, micrognathia, big and low set ears.
    explanation: >-
      Enumerates the characteristic craniofacial dysmorphic features of the
      syndrome.
  downstream:
  - target: Ptosis
    causal_link_type: DIRECT
    description: Periocular developmental dysregulation presents as ptosis.
  - target: Strabismus
    causal_link_type: DIRECT
    description: Ophthalmologic developmental dysregulation presents as strabismus.
  - target: Hypertelorism
    causal_link_type: DIRECT
    description: Midface developmental dysregulation presents as hypertelorism.
  - target: Micrognathia
    causal_link_type: DIRECT
    description: Mandibular developmental dysregulation presents as micrognathia.
  - target: Wide nasal bridge
    causal_link_type: DIRECT
    description: Nasal developmental dysregulation produces a broad, flat nasal bridge.
  - target: Low-set ears
    causal_link_type: DIRECT
    description: Auricular developmental dysregulation presents as large, low-set ears.
- name: GNAL-related basal ganglia dysfunction
  description: >-
    GNAL (at 18p11.21) encodes the alpha subunit of the olfactory G protein
    (G-alpha-olf), and point mutations in GNAL are a major cause of adult-onset
    dystonia. Hemizygosity in 18p deletion carriers confers a low-penetrance
    (~3%) risk of dystonia through impaired striatal G-protein signaling.
  genes:
  - preferred_term: GNAL
    term:
      id: hgnc:4388
      label: GNAL
  biological_processes:
  - preferred_term: G protein-coupled receptor signaling pathway
    modifier: ABNORMAL
    term:
      id: GO:0007186
      label: G protein-coupled receptor signaling pathway
  evidence:
  - reference: PMID:38258373
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A Case of 18p Chromosomal Deletion Encompassing GNAL in a Patient With \nDystonia-Parkinsonism."
    explanation: >-
      Reports a patient with an 18p deletion encompassing GNAL who presented
      with dystonia-parkinsonism, supporting GNAL hemizygosity as a movement-
      disorder mechanism.
  downstream:
  - target: Dystonia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Reduced GNAL dosage impairs striatal signaling and confers a
      low-penetrance risk of dystonia.
- name: SMCHD1-dependent epigenetic derepression
  description: >-
    SMCHD1 (at 18p11.32) is a chromatin modifier that maintains heavy
    methylation of the D4Z4 macrosatellite repeat on chromosome 4q35, repressing
    the DUX4 retrogene. In 18p deletion carriers, SMCHD1 hemizygosity combined
    with a permissive (moderately sized) D4Z4 allele on chromosome 4 can cause
    facioscapulohumeral muscular dystrophy type 2 (FSHD2) through digenic
    inheritance, DUX4 derepression, and muscle degeneration.
  genes:
  - preferred_term: SMCHD1
    term:
      id: hgnc:29090
      label: SMCHD1
  evidence:
  - reference: PMID:29563141
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Digenic inheritance of a SMCHD1 mutation and a moderately sized D4Z4
      repeat on a facioscapulohumeral muscular dystrophy (FSHD) permissive
      genetic background of chromosome 4 can cause FSHD type 2 (FSHD2).
    explanation: >-
      Supports SMCHD1 hemizygosity from 18p deletion as a conditional digenic
      risk factor for FSHD2.
- name: Immune dysregulation
  description: >-
    18p hemizygosity is associated with immunoglobulin deficiency (most notably
    IgA, but also IgG and IgM), predisposing to recurrent infection and
    autoimmunity.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  evidence:
  - reference: PMID:20635794
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunoglobulin (Ig) A deficiency has long been recognized in patients with
      chromosome 18 abnormalities.
    explanation: >-
      Documents IgA deficiency as a recognized immune manifestation of chromosome
      18 abnormalities, including 18p deletion syndrome.
  downstream:
  - target: IgA deficiency
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Impaired immunoglobulin production presents most commonly as IgA
      deficiency.
phenotypes:
- category: Phenotypic
  name: Intellectual disability
  description: >-
    Cognitive impairment, typically in the mild to borderline intellectual
    disability range, is a core feature; deletion extent correlates with
    cognitive outcome.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All the four children with a deletion in the centromeric region at 18p11.1
      had a mental retardation (MR).
    explanation: >-
      Documents intellectual disability (historical term "mental retardation")
      in 18p deletion patients.
- category: Phenotypic
  name: Global developmental delay
  description: >-
    Global developmental delay is recognized in infancy and childhood across the
    18p deletion phenotype.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:39058883
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chromosome 18p deletion syndrome is caused by total or partial deletion of
      the short arm of chromosome 18 and associated with cognitive impairment,
      growth retardation and mild facial dysmorphism.
    explanation: >-
      Supports cognitive impairment / developmental delay as a defining feature.
- category: Phenotypic
  name: Short stature
  description: >-
    Postnatal growth retardation and short stature are common, frequently
    associated with growth-hormone deficiency.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The medical problems are mental and postnatal growth retardation, and
      sometimes malformations of the heart and brain.
    explanation: >-
      Documents postnatal growth retardation, the basis for short stature.
- category: Phenotypic
  name: Growth hormone deficiency
  description: >-
    Isolated growth-hormone deficiency (and less commonly hypopituitarism) is a
    treatable endocrine manifestation mapped to the distal 18p region.
  phenotype_term:
    preferred_term: Growth hormone deficiency
    term:
      id: HP:0000824
      label: Decreased response to growth hormone stimulation test
  evidence:
  - reference: PMID:17786116
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two unrelated children, a 7-month-old girl and a 2-month-old boy had
      del(18p) syndrome and GH deficiency.
    explanation: >-
      Documents growth-hormone deficiency in del(18p) patients.
- category: Phenotypic
  name: Holoprosencephaly
  description: >-
    A holoprosencephaly spectrum, ranging from classic HPE to microforms (e.g.,
    single central incisor), is linked to TGIF1 haploinsufficiency with
    incomplete penetrance.
  phenotype_term:
    preferred_term: Holoprosencephaly
    term:
      id: HP:0001360
      label: Holoprosencephaly
  evidence:
  - reference: PMID:39058883
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Increased nuchal translucency and holoprosencephaly are common prenatal
      phenotypes of distal 18p deletion.
    explanation: >-
      Documents holoprosencephaly as a prenatal phenotype of distal 18p
      deletion.
- category: Phenotypic
  name: Ptosis
  description: >-
    Ptosis is a characteristic periocular craniofacial feature.
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The individuals have some typical features, which might be easy to
      overlook and which are: ptosis, strabismus, hypertelorism, broad flat
      nose, micrognathia, big and low set ears.
    explanation: Lists ptosis among the characteristic features of the syndrome.
- category: Phenotypic
  name: Strabismus
  description: >-
    Strabismus is a common ophthalmologic finding.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The individuals have some typical features, which might be easy to
      overlook and which are: ptosis, strabismus, hypertelorism, broad flat
      nose, micrognathia, big and low set ears.
    explanation: Lists strabismus among the characteristic features of the syndrome.
- category: Phenotypic
  name: Hypertelorism
  description: >-
    Hypertelorism is part of the characteristic facial gestalt.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The individuals have some typical features, which might be easy to
      overlook and which are: ptosis, strabismus, hypertelorism, broad flat
      nose, micrognathia, big and low set ears.
    explanation: Lists hypertelorism among the characteristic features of the syndrome.
- category: Phenotypic
  name: Micrognathia
  description: >-
    Micrognathia is part of the characteristic craniofacial dysmorphism.
  phenotype_term:
    preferred_term: Micrognathia
    term:
      id: HP:0000347
      label: Micrognathia
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The individuals have some typical features, which might be easy to
      overlook and which are: ptosis, strabismus, hypertelorism, broad flat
      nose, micrognathia, big and low set ears.
    explanation: Lists micrognathia among the characteristic features of the syndrome.
- category: Phenotypic
  name: Wide nasal bridge
  description: >-
    A broad, flat nose is part of the characteristic facial gestalt.
  phenotype_term:
    preferred_term: Wide nasal bridge
    term:
      id: HP:0000431
      label: Wide nasal bridge
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The individuals have some typical features, which might be easy to
      overlook and which are: ptosis, strabismus, hypertelorism, broad flat
      nose, micrognathia, big and low set ears.
    explanation: Lists a broad flat nose among the characteristic features of the syndrome.
- category: Phenotypic
  name: Low-set ears
  description: >-
    Large, low-set ears are part of the characteristic craniofacial dysmorphism.
  phenotype_term:
    preferred_term: Low-set ears
    term:
      id: HP:0000369
      label: Low-set ears
  evidence:
  - reference: PMID:16691587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The individuals have some typical features, which might be easy to
      overlook and which are: ptosis, strabismus, hypertelorism, broad flat
      nose, micrognathia, big and low set ears.
    explanation: Lists big, low-set ears among the characteristic features of the syndrome.
- category: Phenotypic
  name: Dystonia
  description: >-
    Dystonia is a low-penetrance, often adult-onset manifestation linked to GNAL
    hemizygosity.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:38258373
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A Case of 18p Chromosomal Deletion Encompassing GNAL in a Patient With \nDystonia-Parkinsonism."
    explanation: >-
      Reports dystonia in an 18p deletion patient with GNAL involvement.
- category: Phenotypic
  name: IgA deficiency
  description: >-
    Decreased circulating IgA (and other immunoglobulin deficiencies) is a
    recognized immune manifestation predisposing to infection and autoimmunity.
  phenotype_term:
    preferred_term: Decreased circulating IgA concentration
    term:
      id: HP:0002720
      label: Decreased circulating IgA concentration
  evidence:
  - reference: PMID:20635794
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The association of specific polysaccharide antibody deficiency, IgA
      deficiency, and chromosome 18p deletion syndrome has not been described
      previously, and extends the immunological phenotype of antibody
      deficiencies associated with defects of chromosome 18.
    explanation: >-
      Documents IgA deficiency directly in a patient with chromosome 18p deletion
      syndrome.
treatments:
- name: Developmental and Behavioral Therapy
  description: >-
    Early intervention with developmental, occupational, and behavioral therapy
    for global developmental delay and intellectual disability.
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: MAXO:0001351
      label: occupational therapy
- name: Speech Therapy
  description: >-
    Speech-language therapy for expressive language delay, common in 18p
    deletion syndrome.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
- name: Physical Therapy
  description: >-
    Physical therapy for hypotonia and motor delay.
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
- name: Growth Hormone Replacement Therapy
  description: >-
    Recombinant growth-hormone (somatropin) replacement for documented growth-
    hormone deficiency, a treatable endocrine manifestation when recognized.
  treatment_term:
    preferred_term: hormone modifying therapy
    term:
      id: MAXO:0000283
      label: hormone modifying therapy
    therapeutic_agent:
    - preferred_term: somatropin
      term:
        id: NCIT:C837
        label: Somatropin
- name: Genetic Counseling
  description: >-
    Genetic counseling regarding the de novo nature of most cases, recurrence
    risk, and genotype-specific anticipatory guidance based on deletion
    breakpoint.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
- name: Multidisciplinary Surveillance
  description: >-
    Supportive, multidisciplinary surveillance including endocrine evaluation
    (growth-hormone testing), immunoglobulin levels, brain MRI, and
    ophthalmologic examination, individualized by deletion extent.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
genetic:
- name: TGIF1 haploinsufficiency
  notes: >-
    TGIF1 (18p11.3) is the key dosage-sensitive gene whose haploinsufficiency is
    implicated in the holoprosencephaly-spectrum and midline brain phenotype of
    monosomy 18p, acting as a repressor in the NODAL/TGF-beta developmental
    signaling pathway.
  gene_term:
    preferred_term: TGIF1
    term:
      id: hgnc:11776
      label: TGIF1
  evidence:
  - reference: PMID:17786116
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Haploinsufficiency for TGIF, mapped to 18p11.3, is not generally
      sufficient to cause HPE.
    explanation: >-
      Identifies TGIF1 (18p11.3) haploinsufficiency as the candidate mechanism
      for holoprosencephaly in monosomy 18p, with incomplete penetrance.
- name: GNAL haploinsufficiency
  notes: >-
    GNAL (18p11.21) is a dosage-sensitive movement-disorder gene; hemizygosity
    in 18p deletion confers a low-penetrance risk of dystonia.
  gene_term:
    preferred_term: GNAL
    term:
      id: hgnc:4388
      label: GNAL
  evidence:
  - reference: PMID:38258373
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A Case of 18p Chromosomal Deletion Encompassing GNAL in a Patient With \nDystonia-Parkinsonism."
    explanation: >-
      Documents GNAL involvement in an 18p deletion patient with dystonia.
- name: SMCHD1 haploinsufficiency
  notes: >-
    SMCHD1 (18p11.32) is a chromatin modifier; hemizygosity in 18p deletion is a
    conditional digenic risk factor for FSHD2 on a permissive chromosome 4q
    background.
  gene_term:
    preferred_term: SMCHD1
    term:
      id: hgnc:29090
      label: SMCHD1
  evidence:
  - reference: PMID:29563141
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among other genes, structural maintenance of chromosomes flexible hinge
      domain containing 1 (SMCHD1) is hemizygous in most patients with 18p
      deletions.
    explanation: >-
      Documents SMCHD1 hemizygosity in most 18p deletion patients, the basis for
      conditional FSHD2 risk.
📚

References & Deep Research

References

1
PMID:26250845
A review of 18p deletions.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 7 citations 2026-06-22T12:44:21.552216

1. Disease Information

Overview

Chromosome 18p deletion syndrome (also known as monosomy 18p, 18p- syndrome, or 18p deletion syndrome) is a rare chromosomal disorder characterized by partial or complete loss of the short arm of chromosome 18 (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 1-2). First described by de Grouchy and colleagues in 1963, it is one of the most frequent autosomal terminal deletion syndromes and was the first reported partial monosomy compatible with life (papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 1-2). The syndrome presents with highly variable clinical features including cognitive impairment, minor facial dysmorphism, strabismus, ptosis, short stature, and systemic involvement affecting multiple organ systems (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 7-8).

Key Identifiers

  • OMIM: #146390 (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3)
  • Orphanet: Not explicitly stated in retrieved literature, but the condition is recognized as a rare disease
  • ICD Codes: Not explicitly provided in retrieved sources
  • MeSH: Not explicitly provided in retrieved sources
  • MONDO ID: Not explicitly provided in retrieved sources

Synonyms and Alternative Names

  • Monosomy 18p (papamichail2024prenataldiagnosisof pages 1-3, oktay202518pdeletionsyndrome pages 1-2)
  • 18p- syndrome (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4)
  • 18p deletion syndrome (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3)
  • Chromosome 18p deletion syndrome (papamichail2024prenataldiagnosisof pages 1-3)

Data Source Type

The information is derived from both individual patient case reports and aggregated disease-level resources, including a comprehensive cohort study of 106 individuals (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4).

2. Etiology

Disease Causal Factors

Chromosome 18p deletion syndrome is caused by a chromosomal deletion affecting the short arm (p arm) of chromosome 18 (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4). The deletion size and breakpoint location vary significantly between individuals, contributing to phenotypic heterogeneity (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4). Approximately 42% of cases have breakpoints within the centromeric region, while the remaining breakpoints are scattered along the entirety of the short arm (hasi‐zogaj2015areviewof pages 2-4, hasi‐zogaj2015areviewof pages 4-7). Interestingly, no large interstitial deletions of 18p have been reported, though microdeletions have been documented (hasi‐zogaj2015areviewof pages 2-4).

Risk Factors

Genetic Risk Factors: The primary genetic risk factor is the presence of a balanced chromosomal translocation in a parent, particularly involving chromosome 18p and an acrocentric chromosome (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 11-12). Approximately 89% of cases arise de novo, while ~11% are inherited or result from unbalanced translocations (hasi‐zogaj2015areviewof pages 2-4). Of de novo cases where parental origin can be determined, approximately 50% arise from the maternal chromosome and 50% from the paternal chromosome (hasi‐zogaj2015areviewof pages 2-4).

Specific Causal/Modifier Genes (Haploinsufficiency): - TGIF1 (3,451,591-3,458,406 on 18p): Haploinsufficiency causes holoprosencephaly (HPE) and HPE microforms with ~11% penetrance in deletion carriers (hasi‐zogaj2015areviewof pages 4-7, hasi‐zogaj2015areviewof pages 7-8) - SMCHD1 (2,655,886-2,805,015): Conditional haploinsufficiency; individuals with 18p deletion plus a permissive D4Z4 allele on chromosome 4q are at risk for facioscapulohumeral muscular dystrophy type 2 (FSHD2) (hasi‐zogaj2015areviewof pages 8-9, balog2018monosomy18pis pages 1-3) - GNAL (11,689,014-11,885,683): Linked to dystonia with low penetrance (~3% in deletion carriers) (hasi‐zogaj2015areviewof pages 7-8) - PTPN2 (12,792,301-12,884,334): Associated with autoimmune disease risk including rheumatoid arthritis, thyroiditis, and other autoimmune conditions (hasi‐zogaj2015areviewof pages 8-9, oktay202518pdeletionsyndrome pages 1-2) - AFG3L2 (12,328,943-12,377,275): Potential risk for spinocerebellar ataxia type 28 (SCA28), though not yet manifested in young cohorts (hasi‐zogaj2015areviewof pages 8-9, hasi‐zogaj2015areviewof pages 10-11) - LAMA1 (6,941,743-7,117,813): Associated with retinal vascular anomalies and possible skin findings (keratosis pilaris/ulerythema ophryogenes) (hasi‐zogaj2015areviewof pages 7-8)

Environmental/Other Risk Factors: No specific environmental risk factors for developing the deletion have been identified. However, TGIF1 heterozygous knockout mice exposed prenatally to retinoic acid show significantly increased risk for facial deformities, holoprosencephaly, and neural tube defects, suggesting potential gene-environment interactions (hasi‐zogaj2015areviewof pages 9-10).

Protective Factors

No genetic or environmental protective factors have been identified in the literature.

Gene-Environment Interactions

The TGIF1/TWSG1 genes, when hemizygous, may interact with retinoic acid or other environmental factors during embryonic development to modulate HPE risk, as demonstrated in mouse models (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 11-12).

3. Phenotypes

The clinical phenotype of chromosome 18p deletion syndrome is highly variable, with significant differences even among individuals with identical breakpoints, indicating incomplete penetrance and expressivity for most features (papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 1-2). A comprehensive phenotype table is provided below.

Phenotype Frequency in centromeric 18p- cohort Suggested HPO term(s) Typical onset Usual severity / course Notes / evidence
Hypotonia / mixed tone abnormalities 84% HP:0001252 Hypotonia; HP:0003808 Abnormality of muscle tone Neonatal–infancy Mild to moderate; often persistent developmental impact Common early neurologic feature in centromeric 18p- (hasi‐zogaj2015areviewof pages 7-8)
Neonatal complications (jaundice, respiratory distress, feeding difficulties) 71% HP:0001945 Respiratory distress; HP:0011968 Feeding difficulties; HP:0002904 Neonatal hypoglycemia/jaundice not specifically resolved Neonatal Variable; may require supportive care Composite category reported in review table (hasi‐zogaj2015areviewof pages 7-8)
MRI anomalies (excluding holoprosencephaly spectrum) 66% HP:0410263 Abnormal brain MRI; HP:0002538 Abnormal cerebral white matter morphology Congenital / childhood recognition Variable; often nonprogressive structural findings White matter abnormalities and other MRI findings frequently observed (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 9-10)
Recurrent otitis media 61% HP:0000389 Recurrent otitis media Infancy–childhood Recurrent; may contribute to conductive hearing loss Often associated with chronic middle-ear disease (hasi‐zogaj2015areviewof pages 7-8)
Heart defects 56% HP:0001627 Abnormality of the cardiovascular system; HP:0001629 Ventricular septal defect; HP:0001636 Tetralogy of Fallot Congenital Variable from mild to surgically significant Structural cardiac defects are common; prenatal VSD also reported (hasi‐zogaj2015areviewof pages 7-8, papamichail2023prenataldiagnosisof pages 1-3)
Ptosis 55% HP:0000508 Ptosis Congenital / infancy Mild to moderate; often persistent Characteristic craniofacial/ophthalmic feature (hasi‐zogaj2015areviewof pages 7-8)
Refractive errors 52% HP:0000545 Myopia; HP:0000539 Refractive error Childhood Mild to moderate; usually manageable with correction Broad ophthalmic involvement is frequent (hasi‐zogaj2015areviewof pages 7-8)
Strabismus 42% HP:0000486 Strabismus Infancy–childhood Mild to moderate; may need ophthalmologic management Common visual alignment abnormality (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11)
Pectus excavatum 29% HP:0000767 Pectus excavatum Childhood Usually mild to moderate; generally stable Skeletal/chest wall manifestation (hasi‐zogaj2015areviewof pages 7-8)
Hearing loss (overall) 23% HP:0000365 Hearing impairment; HP:0000405 Conductive hearing impairment; HP:0000407 Sensorineural hearing impairment Childhood Usually mild to moderate; conductive more common than sensorineural Review table reports hearing loss overall 23%; critical-region analysis separated conductive 22% and sensorineural 8% penetrance (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11)
Isolated growth hormone deficiency 23% HP:0000824 Growth hormone deficiency; HP:0001510 Growth delay Childhood Variable; treatable when recognized Endocrine surveillance recommended in review (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11)
Scoliosis / kyphosis 19% HP:0002650 Scoliosis; HP:0002808 Kyphosis Childhood–adolescence Mild to moderate; occasionally requires bracing/surgery Combined axial skeletal phenotype (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11)
Pes planus 19% HP:0001763 Pes planus Childhood Usually mild; may affect gait/endurance Common orthopedic feature (hasi‐zogaj2015areviewof pages 7-8)
Cryptorchidism 14% HP:0000028 Cryptorchidism Congenital Variable; may require orchiopexy Male genital anomaly; micropenis also described in prenatal case literature (hasi‐zogaj2015areviewof pages 7-8, papamichail2023prenataldiagnosisof pages 1-3)
Panhypopituitarism / hypopituitarism 13% HP:0000826 Hypopituitarism; HP:0000873 Panhypopituitarism Congenital / childhood Potentially severe; chronic hormone replacement often required Includes structural pituitary anomalies in some patients (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 9-10)
Seizures 13% HP:0001250 Seizure Childhood Variable; often intermittent/managed medically Included grand mal, absence, and partial complex seizures in review cohort (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11)
Immunoglobulin deficiency (IgA, IgG, or IgM deficiency) 13% HP:0002721 Immunodeficiency; HP:0002205 Recurrent infections; HP:0011347 Decreased circulating IgA level Childhood Variable; may predispose to infections/autoimmunity IgA deficiency specifically reported in review and later case reports (hasi‐zogaj2015areviewof pages 7-8, oktay202518pdeletionsyndrome pages 1-2)
Holoprosencephaly or HPE microform 13% HP:0001360 Holoprosencephaly; HP:0000668 Single central incisor Prenatal / congenital Severe in classic HPE, milder in microforms TGIF1 hemizygosity is a major mechanistic candidate; penetrance incomplete (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 4-7)
Autoimmune disorder 10% HP:0002960 Autoimmunity; HP:0000821 Hypothyroidism; HP:0002725 Systemic lupus erythematosus; HP:0012205 Alopecia Childhood–adult Variable; chronic, organ-specific or systemic Review lists rheumatoid arthritis, celiac disease, alopecia, vitiligo, lupus, Sjögren syndrome, autoimmune thyroid disease (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 9-10, oktay202518pdeletionsyndrome pages 1-2)
Sacral agenesis 6% HP:0003310 Sacral agenesis Congenital Moderate to severe; structural Rare but recurrent caudal malformation (hasi‐zogaj2015areviewof pages 7-8)
Optic nerve hypoplasia 6% HP:0008058 Optic nerve hypoplasia Congenital / infancy Variable visual impairment Part of ophthalmologic/neurodevelopmental spectrum (hasi‐zogaj2015areviewof pages 7-8)
Congenital cataracts 6% HP:0000519 Congenital cataract Congenital Variable; may need surgery Rare but documented ocular feature (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11)
Myelomeningocele 3% HP:0002414 Myelomeningocele Congenital Severe structural defect Uncommon neural tube defect in reported cohort (hasi‐zogaj2015areviewof pages 7-8)

Table: This table summarizes the principal phenotypes reported in the comprehensive Hasi-Zogaj 2015 review of chromosome 18p deletion syndrome, including frequencies, suggested HPO mappings, onset, and usual severity/course. It is useful for knowledge-base phenotype annotation and anticipatory clinical assessment.

Quality of Life Impact

Individuals with chromosome 18p deletion syndrome experience significant impacts on quality of life related to: - Cognitive Function: Average full-scale IQ of 69 (range 51-99), typically in the mild to borderline intellectual disability range (hasi‐zogaj2015areviewof pages 2-4) - Adaptive Functioning: The majority of participants have problems with activities of everyday life, including difficulties with communication, home living, self-care, and management of social and leisure activities (hasi‐zogaj2015areviewof pages 2-4) - Autism Spectrum Features: Based on parental report using the Gilliam Autism Rating Scale (GARS), between 19% and 38% of individuals score in the range suggesting autism spectrum disorder (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9) - Medical Complications: Chronic medical issues including recurrent otitis media (61%), cardiac anomalies requiring management (56%), endocrine dysfunction (23-13%), and sensory impairments significantly impact daily functioning (hasi‐zogaj2015areviewof pages 7-8)

4. Genetic/Molecular Information

Chromosomal Abnormalities

Chromosome 18p deletion syndrome is characterized by partial or complete monosomy of the short arm of chromosome 18 (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4). The deletions are predominantly terminal, with breakpoints ranging from the centromere to various positions along the p arm (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4, hasi‐zogaj2015areviewof pages 4-7).

Deletion Characteristics: - Size: Variable, ranging from small microdeletions (<1 Mb) to complete p-arm deletions (~15-17 Mb) (papamichail2024prenataldiagnosisof pages 1-3, oktay202518pdeletionsyndrome pages 1-2) - Breakpoint distribution: ~42% centromeric, ~58% scattered along 18p (hasi‐zogaj2015areviewof pages 2-4) - Type: Predominantly terminal deletions; no large interstitial deletions reported (hasi‐zogaj2015areviewof pages 2-4) - Origin: ~89% de novo, ~11% familial (inherited or translocation-derived) (hasi‐zogaj2015areviewof pages 2-4) - Parental origin of de novo cases: ~50% maternal, ~50% paternal (hasi‐zogaj2015areviewof pages 2-4)

Unbalanced Translocations: Unbalanced translocations, particularly between 18p and acrocentric chromosomes (13, 15, 21, 22), account for a subset of cases (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 11-12). These often arise from parental balanced translocations or pericentric inversions (hasi‐zogaj2015areviewof pages 1-2).

Pathogenic Variants and Causal Genes

The syndrome results from structural chromosomal abnormalities (deletions, unbalanced translocations) rather than point mutations (hasi‐zogaj2015areviewof pages 1-2). A comprehensive gene dosage map has been established, identifying 12 genes as likely or possibly dosage-sensitive out of 67 total genes on 18p (hasi‐zogaj2015areviewof pages 2-4, hasi‐zogaj2015areviewof pages 10-11). A detailed gene table is provided below.

Gene 18p location (hg19, as reported) Core function Haploinsufficiency / dosage status in review Phenotypes linked to hemizygosity or conditional hemizygosity Inheritance / mechanistic model Key evidence from Hasi-Zogaj 2015 review
CETN1 580,369-581,524 Centrin family protein involved in centrosome position/segregation and microtubule functions Not established as pathogenic for a human 18p- phenotype; discussed as a candidate dosage-sensitive gene No specific confirmed human phenotype from 18p hemizygosity; possible relevance to male fertility considered but unproven Unclear; no direct phenotype established in 18p-; maternal transmissions including this region argue against female infertility Review notes mouse heterozygous mutations cause infertility, but human 18p deletions including CETN1 have been maternally transmitted; no firm human dosage phenotype assigned (hasi‐zogaj2015areviewof pages 4-7)
TGIF1 3,451,591-3,458,406 Homeodomain transcriptional regulator in TGF-beta/NODAL-related developmental signaling Likely dosage-sensitive / haploinsufficient Holoprosencephaly (HPE), HPE microforms, single central incisor, midline/pituitary anomalies Classic haploinsufficiency with incomplete penetrance; phenotype modified by additional factors In the review cohort, 11% (6/65) of individuals hemizygous for TGIF1 had HPE-spectrum malformations; TGIF1 point mutations are established in HPE and 18p hemizygosity is a recognized risk factor (hasi‐zogaj2015areviewof pages 4-7, hasi‐zogaj2015areviewof pages 7-8)
DLGAP1 3,499,183-3,880,068 Postsynaptic density scaffold protein Candidate dosage-sensitive / possible risk gene Autism spectrum disorder / autistic features Risk-factor model rather than fully penetrant haploinsufficiency Seven of eight individuals with clinically significant autism scores had deletions including DLGAP1; proposed because of postsynaptic density enrichment (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9)
TWSG1 9,334,765-9,402,418 BMP-binding extracellular developmental regulator involved in dorsal-ventral patterning and craniofacial development Conditional / uncertain dosage sensitivity Possible modifier for HPE; possible contribution to dental/caries phenotype; direct role in 18p HPE not proven Likely modifier-gene model, potentially interacting with TGIF1 or environmental exposures Review states evidence for direct involvement in HPE is conflicting; no study participant with isolated TWSG1 hemizygosity had HPE, though prior literature suggested combined deletion with TGIF1 may increase HPE penetrance (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 11-12)
ANKRD12 9,136,751-9,285,983 Ankyrin repeat domain-containing protein; exact dosage mechanism uncertain Candidate conditional dosage-sensitive / risk gene Autism spectrum disorder risk Risk-factor model Listed among 18p genes implicated by overlap in individuals with clinically significant autism scores (hasi‐zogaj2015areviewof pages 8-9)
LAMA1 6,941,743-7,117,813 Laminin alpha-1, basement membrane component Likely dosage-sensitive / conditional Retinal vascular anomalies, keratosis pilaris / ulerythema ophryogenes candidate, possible ocular/cerebellar features Incomplete penetrance; possible revealed recessive-allele model for severe manifestations In the cohort, 1/32 with LAMA1 hemizygosity had tortuous anomalous retinal vessels; skin findings were common but nonspecific; review discusses relevance based on known recessive LAMA1 disease and mouse retinal vasculopathy (hasi‐zogaj2015areviewof pages 7-8)
LRRC30 7,231,137-7,232,042 Leucine-rich repeat-containing protein; function poorly defined Candidate conditional dosage-sensitive / risk gene Autism spectrum disorder risk Risk-factor model Included among genes recurrently deleted in individuals with autism-range GARS/GARS-2 scores (hasi‐zogaj2015areviewof pages 8-9)
GNAL 11,689,014-11,885,683 G-protein alpha-olf subunit involved in receptor signaling Likely dosage-sensitive / conditional Dystonia, torsion dystonia, movement disorders Conditional / incompletely penetrant haploinsufficiency GNAL is a major adult-onset dystonia gene in the literature; in the 18p- cohort, 2/58 individuals with deletions encompassing GNAL had dystonia, supporting low-penetrance risk from hemizygosity (hasi‐zogaj2015areviewof pages 7-8)
IMPA2 11,981,427-12,030,885 Inositol monophosphatase-related function Candidate conditional dosage-sensitive / risk gene Autism spectrum disorder risk Risk-factor model Seven of eight autism-range cases had deletions including DLGAP1/LRRC30/ANKRD12/IMPA2; one additional case lacked IMPA2, suggesting it may contribute but is not solely causal (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9)
AFG3L2 12,328,943-12,377,275 Mitochondrial protease subunit involved in protein quality control and ribosome assembly Conditional dosage-sensitive Spinocerebellar ataxia type 28 (SCA28)-like risk; possible later-onset ataxia Conditional haploinsufficiency / age-dependent penetrance None of 15 examined individuals met diagnostic criteria for SCA28, but point mutations in AFG3L2 cause dominant ataxia and the review highlights possible future age-related manifestation in 18p- adults (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11)
PTPN2 12,792,301-12,884,334 Protein tyrosine phosphatase involved in immune regulation Conditional dosage-sensitive / susceptibility gene Autoimmune disease risk (juvenile rheumatoid arthritis, thyroid autoimmunity, celiac disease, vitiligo, psoriasis, alopecia, Sjogren syndrome) Susceptibility / second-hit model No inflammatory bowel disease was seen in 67 hemizygous individuals, but 11 had autoimmune conditions; the review considers PTPN2 a plausible contributor with incomplete penetrance and likely additional modifiers (hasi‐zogaj2015areviewof pages 8-9)
SMCHD1 2,655,886-2,805,015 Structural maintenance of chromosomes hinge domain protein; chromatin repression and methylation including D4Z4 Conditional dosage-sensitive Risk for facioscapulohumeral muscular dystrophy type 2 (FSHD2), retinal vasculopathy in susceptible background Digenic / permissive-background model requiring hemizygosity plus permissive D4Z4 allele and repeat context Review states SMCHD1 hemizygosity alone is insufficient, but individuals with 18p deletion may be at risk for FSHD when a permissive 4q D4Z4 background is present; this was later directly supported by Balog et al. 2018 (hasi‐zogaj2015areviewof pages 8-9, balog2018monosomy18pis pages 1-3)
PTPRM Not specified in the review pages provided Receptor-type protein tyrosine phosphatase Not classified in Hasi-Zogaj 2015 as a key dosage-sensitive gene No specific phenotype assigned in the review Unclear Mentioned in later case literature on 18p autoimmunity, but not among the key mapped dosage-sensitive genes in the Hasi-Zogaj review sections provided (oktay202518pdeletionsyndrome pages 1-2)
ADCYAP1 Not specified in the review pages provided Pituitary adenylate cyclase-activating polypeptide signaling Not classified in Hasi-Zogaj 2015 as a key dosage-sensitive gene No specific phenotype assigned in the review Unclear Reported in later case literature as a potentially relevant deleted gene in autoimmune endocrinopathy, but not a mapped key dosage-sensitive gene in the review (oktay202518pdeletionsyndrome pages 1-2)
LPIN2 Not specified in the review pages provided Lipin-2, lipid metabolism/inflammation-related protein Not classified in Hasi-Zogaj 2015 as a key dosage-sensitive gene No specific phenotype assigned in the review Unclear Highlighted in a later autoimmune case report, not as a core dosage-sensitive 18p review gene (oktay202518pdeletionsyndrome pages 1-2)
USP14 Not specified in the review pages provided Deubiquitinating enzyme involved in proteostasis Not classified in Hasi-Zogaj 2015 as a key dosage-sensitive gene No specific phenotype assigned in the review Unclear Cited in later case literature as a potentially relevant deleted immune-modifying gene, but not part of the core 2015 dosage map summarized here (oktay202518pdeletionsyndrome pages 1-2)

Table: This table summarizes the principal chromosome 18p genes discussed as dosage-sensitive, conditionally dosage-sensitive, or candidate risk genes in the Hasi-Zogaj 2015 review, with later context for several immune-related genes. It is useful for linking deletion breakpoints to expected phenotypes and for distinguishing established haploinsufficiency from low-penetrance or modifier effects.

Allele Frequency

As a predominantly de novo chromosomal abnormality, there is no meaningful population allele frequency for specific deletion variants.

Somatic vs. Germline

The deletions are germline events, present in all cells of affected individuals (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4).

Epigenetic Information

SMCHD1 hemizygosity specifically impacts DNA methylation and chromatin structure. SMCHD1 is responsible for maintaining methylation of the D4Z4 chromatin domain on chromosome 4q; its loss results in hypomethylation similar to FSHD2, potentially leading to inappropriate DUX4 expression when combined with a permissive genetic background (hasi‐zogaj2015areviewof pages 8-9, balog2018monosomy18pis pages 1-3).

5. Environmental Information

No specific environmental factors (toxins, radiation, pollution, occupational exposures) have been identified as causative or modifying factors for chromosome 18p deletion syndrome. The deletions arise predominantly as sporadic chromosomal rearrangement events during gametogenesis or early embryonic development (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4).

6. Mechanism / Pathophysiology

Molecular Pathways

TGF-beta/NODAL Signaling (TGIF1): TGIF1 encodes a homeodomain protein that functions as a transcriptional regulator in the TGF-beta and NODAL signaling pathways, critical for dorsal-ventral patterning and midline development during embryogenesis (hasi‐zogaj2015areviewof pages 4-7, hasi‐zogaj2015areviewof pages 11-12). Haploinsufficiency leads to holoprosencephaly spectrum disorders with incomplete penetrance (~11%) (hasi‐zogaj2015areviewof pages 4-7). Point mutations in TGIF1 are established causes of HPE, and 18p hemizygosity represents a genomic mechanism for the same phenotype (hasi‐zogaj2015areviewof pages 4-7). - Suggested GO terms: GO:0007389 (pattern specification process), GO:0001942 (hair follicle development), GO:0030509 (BMP signaling pathway)

Postsynaptic Density Function (DLGAP1, ANKRD12, IMPA2, LRRC30): These genes encode proteins enriched in or associated with the postsynaptic density, a specialized structure at excitatory synapses (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9). Hemizygosity of these genes, particularly DLGAP1, is associated with increased risk of autism spectrum features, likely through disruption of synaptic signaling and plasticity (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9). - Suggested GO terms: GO:0014069 (postsynaptic density), GO:0099151 (regulation of postsynaptic density organization), GO:0099560 (synaptic membrane adhesion)

G-protein Signaling (GNAL): GNAL encodes the α-subunit of the G-protein olfactory receptor (Golf) involved in neuronal signaling (hasi‐zogaj2015areviewof pages 7-8). Point mutations in GNAL are a major cause of adult-onset dystonia, and hemizygosity in 18p deletion carries a low-penetrance risk (~3%) for dystonia (hasi‐zogaj2015areviewof pages 7-8). - Suggested GO terms: GO:0007186 (G-protein coupled receptor signaling pathway), GO:0007268 (chemical synaptic transmission)

Mitochondrial Protein Quality Control (AFG3L2): AFG3L2 encodes a subunit of a mitochondrial protease critical for degrading misfolded proteins and ribosome assembly (hasi‐zogaj2015areviewof pages 8-9, hasi‐zogaj2015areviewof pages 10-11). Point mutations cause spinocerebellar ataxia type 28 (SCA28) with dominant inheritance. Hemizygosity may confer age-dependent risk for ataxia, though this has not yet manifested in relatively young cohorts (hasi‐zogaj2015areviewof pages 8-9, hasi‐zogaj2015areviewof pages 10-11). - Suggested GO terms: GO:0006515 (protein quality control for misfolded or incompletely synthesized proteins), GO:0034983 (peptidyl-lysine deacetylation)

Immune Regulation (PTPN2): PTPN2 encodes a protein tyrosine phosphatase involved in immune regulation. GWAS studies and mouse models link PTPN2 to inflammatory bowel disease, rheumatoid arthritis, and type 1 diabetes (hasi‐zogaj2015areviewof pages 8-9, oktay202518pdeletionsyndrome pages 1-2). In 18p deletion, hemizygosity is associated with autoimmune conditions (~11% penetrance) including thyroid autoimmunity, rheumatoid arthritis, celiac disease, and others, suggesting a susceptibility/second-hit model (hasi‐zogaj2015areviewof pages 8-9, oktay202518pdeletionsyndrome pages 1-2). - Suggested GO terms: GO:0002376 (immune system process), GO:0050776 (regulation of immune response), GO:0002250 (adaptive immune response)

Chromatin Methylation and FSHD2 (SMCHD1): SMCHD1 is a chromatin modifier responsible for maintaining heavy methylation of the D4Z4 macrosatellite repeat on chromosome 4q35, thereby repressing the DUX4 retrogene (hasi‐zogaj2015areviewof pages 8-9, balog2018monosomy18pis pages 1-3). In FSHD2, digenic inheritance of SMCHD1 haploinsufficiency (from 18p deletion or point mutation) plus a moderately sized, permissive D4Z4 allele leads to chromatin relaxation, DUX4 derepression, and muscle degeneration (hasi‐zogaj2015areviewof pages 8-9, balog2018monosomy18pis pages 1-3). Approximately 12% of Caucasians harbor a permissive genetic background, placing individuals with 18p deletion at conditional risk (balog2018monosomy18pis pages 1-3). - Suggested GO terms: GO:0006325 (chromatin organization), GO:0006346 (DNA methylation-dependent heterochromatin formation)

Basement Membrane Integrity (LAMA1): LAMA1 encodes laminin alpha-1, a basement membrane protein expressed in renal cortex, testis, and retina (hasi‐zogaj2015areviewof pages 7-8). In mice, LAMA1 mutations cause retinal vasculopathy with vessel tortuosity. Recessive LAMA1 mutations in humans cause Poretti-Bolshauser syndrome (cerebellar anomalies, retinal dystrophy). Hemizygosity in 18p deletion may contribute to retinal vascular anomalies (~3% documented) and potentially skin findings (keratosis pilaris) (hasi‐zogaj2015areviewof pages 7-8). - Suggested GO terms: GO:0005604 (basement membrane), GO:0001570 (vasculogenesis)

Cellular Processes

  • Neurodevelopmental patterning defects: TGIF1 and TWSG1 haploinsufficiency during embryogenesis (hasi‐zogaj2015areviewof pages 4-7, hasi‐zogaj2015areviewof pages 9-10)
  • Synaptic dysfunction: Postsynaptic density protein deficiency (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9)
  • Mitochondrial stress and proteostasis: AFG3L2 haploinsufficiency (hasi‐zogaj2015areviewof pages 8-9, hasi‐zogaj2015areviewof pages 10-11)
  • Immune dysregulation: PTPN2 haploinsufficiency (hasi‐zogaj2015areviewof pages 8-9, oktay202518pdeletionsyndrome pages 1-2)

Tissue Damage Mechanisms

Chronic otitis media leading to conductive hearing loss involves middle ear mucosal dysfunction, possibly related to TGIF1 or other gene hemizygosity affecting epithelial integrity (hasi‐zogaj2015areviewof pages 7-8).

7. Anatomical Structures Affected

Organ Level

Primary Organs Directly Affected: - Brain: 66% of individuals have MRI anomalies including white matter abnormalities, holoprosencephaly spectrum (13%), pituitary anomalies (13%), and structural changes (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 9-10) - UBERON terms: UBERON:0000955 (brain), UBERON:0002037 (cerebellum), UBERON:0000007 (pituitary gland) - Heart: 56% have cardiac defects including ventricular septal defects, tetralogy of Fallot, and other structural anomalies (hasi‐zogaj2015areviewof pages 7-8) - UBERON term: UBERON:0000948 (heart) - Eyes: 52-55% have ophthalmologic findings including ptosis, strabismus, refractive errors, and rare retinal vascular anomalies (hasi‐zogaj2015areviewof pages 7-8) - UBERON term: UBERON:0000970 (eye) - Endocrine System: 23% isolated growth hormone deficiency, 13% panhypopituitarism/hypopituitarism (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 9-10) - UBERON term: UBERON:0000949 (endocrine system) - Immune System: 13% immunoglobulin deficiency, 10% autoimmune disorders (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 9-10, oktay202518pdeletionsyndrome pages 1-2) - UBERON term: UBERON:0002405 (immune system) - Ears: 61% recurrent otitis media, 23% hearing loss (hasi‐zogaj2015areviewof pages 7-8) - UBERON term: UBERON:0001690 (ear)

Secondary Organ Involvement: - Musculoskeletal: Hypotonia (84%), scoliosis/kyphosis (19%), pectus excavatum (29%), pes planus (19%) (hasi‐zogaj2015areviewof pages 7-8) - UBERON term: UBERON:0002204 (musculoskeletal system)

Tissue and Cell Level

Specific cell populations targeted include: - Neurons and postsynaptic structures (autism risk associated with synaptic gene haploinsufficiency) (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9) - Cell Ontology term: CL:0000540 (neuron) - Pituitary somatotrophs and other endocrine cells (growth hormone deficiency) (hasi‐zogaj2015areviewof pages 7-8) - Cell Ontology term: CL:0000441 (somatotroph) - Immune cells (B-cells and T-cells) (immunoglobulin deficiency, autoimmunity) (hasi‐zogaj2015areviewof pages 7-8, oktay202518pdeletionsyndrome pages 1-2) - Cell Ontology terms: CL:0000236 (B cell), CL:0000084 (T cell)

Subcellular Level

  • Postsynaptic density (DLGAP1 function) (hasi‐zogaj2015areviewof pages 9-10)
  • GO Cellular Component term: GO:0014069 (postsynaptic density)
  • Mitochondria (AFG3L2 protease function) (hasi‐zogaj2015areviewof pages 8-9, hasi‐zogaj2015areviewof pages 10-11)
  • GO Cellular Component term: GO:0005739 (mitochondrion)
  • Chromatin/nucleus (SMCHD1 methylation function) (hasi‐zogaj2015areviewof pages 8-9)
  • GO Cellular Component term: GO:0000785 (chromatin)

8. Temporal Development

Onset

  • Typical Age of Onset: Congenital for structural anomalies (holoprosencephaly, cardiac defects, dysmorphic features); neonatal for hypotonia and feeding difficulties; childhood for developmental delay recognition and medical complications; potentially adult-onset for dystonia, FSHD2, and some autoimmune features (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 2-4)
  • Onset Pattern: Predominantly congenital with chronic/progressive manifestations through childhood and adulthood (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4)

Progression

  • Disease Stages: No formal staging system; clinical presentation evolves from congenital structural defects through developmental delays in childhood to potential adult complications (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4)
  • Progression Rate: Variable; cognitive impairment is relatively stable (average IQ 69), while medical complications can accumulate over time (hasi‐zogaj2015areviewof pages 2-4)
  • Disease Course Pattern: Chronic, lifelong condition with stable cognitive baseline and variable medical complications (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4)
  • Disease Duration: Lifelong (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4)

Patterns

  • Remission Patterns: Not applicable; this is a chromosomal condition without remission (hasi‐zogaj2015areviewof pages 1-2)
  • Critical Periods: Embryonic development (for structural malformations related to TGIF1/TWSG1), early childhood (for developmental intervention), adolescence/adulthood (for monitoring dystonia, FSHD2, autoimmune disease risk) (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 4-7, hasi‐zogaj2015areviewof pages 8-9)

9. Inheritance and Population

Epidemiology

  • Prevalence: Approximately 1 in 50,000 live births (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3)
  • Incidence: Not separately reported; presumed similar to prevalence given lifelong nature
  • Sex Ratio: Female to male ratio of 3:2 (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3)

Genetic Etiology and Inheritance

  • Inheritance Pattern: Predominantly de novo (~89% of cases); ~11% familial, arising from unbalanced segregation of parental balanced translocations or direct parent-to-child transmission (hasi‐zogaj2015areviewof pages 2-4, hasi‐zogaj2015areviewof pages 11-12)
  • Penetrance:
  • Complete penetrance for the chromosomal abnormality itself
  • Incomplete penetrance for specific phenotypes: TGIF1 → HPE (11%), GNAL → dystonia (3%), SMCHD1 → FSHD2 (conditional on 4q background), PTPN2 → autoimmunity (~11-17%) (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 4-7, hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9)
  • Expressivity: Highly variable even with identical breakpoints, indicating modifier genes and environmental factors influence phenotype (papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 1-2)
  • Genetic Anticipation: Not documented (no trinucleotide repeat mechanism)
  • Germline Mosaicism: Not specifically reported in retrieved literature
  • Founder Effects: Not reported; no population-specific variants identified
  • Consanguinity Role: Not relevant for de novo deletions; may unmask recessive alleles in deleted regions (theoretical)
  • Carrier Frequency: Not applicable for de novo events; parental balanced translocation carriers exist but specific frequency not documented

Population Demographics

  • Affected Populations: No specific ethnic or demographic groups with higher prevalence reported; cases described across multiple populations (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 1-2)
  • Geographic Distribution: Worldwide distribution; no endemic areas identified (hasi‐zogaj2015areviewof pages 1-2)
  • Age Distribution: Congenital condition with lifelong manifestations; cohorts studied range from neonates to adults (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 2-4)

10. Diagnostics

Genetic Testing

Recommended Genetic Testing Approach: Chromosomal microarray analysis (CMA) / array-based comparative genomic hybridization (array-CGH) is the primary diagnostic method, providing sensitive detection of deletions and precise breakpoint mapping (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 2-4). CMA can detect submicroscopic deletions missed by conventional karyotyping and is considered first-tier testing for developmental delay/intellectual disability (papamichail2024prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 2-4).

Specific Methods: - Chromosomal Microarray (CMA): Detects deletions, defines breakpoints, and identifies size of deleted region; current technology uses 400K-750K oligonucleotide platforms (papamichail2024prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 2-4) - Karyotyping: Useful for identifying gross deletions and, critically, for detecting balanced translocations in parents (papamichail2024prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 11-12). Parental testing is recommended, especially if there is a family history of cognitive impairment, congenital anomalies, or recurrent pregnancy loss (hasi‐zogaj2015areviewof pages 11-12) - FISH (Fluorescence In Situ Hybridization): Can confirm specific deletions but is targeted rather than genome-wide (papamichail2024prenataldiagnosisof pages 1-3) - Prenatal Testing: CMA can be performed on chorionic villus sampling (CVS) or amniocentesis samples; however, prenatal phenotype prediction is challenging due to variable expressivity (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3)

Clinical Tests

Laboratory Tests: - Immunoglobulin levels (IgA, IgG, IgM): To detect immunodeficiency (13% affected) (hasi‐zogaj2015areviewof pages 7-8) - Endocrine evaluation: Growth hormone stimulation testing, thyroid function tests, complete pituitary hormone panel for individuals with growth failure or pituitary structural anomalies (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 9-10) - Autoimmune markers: Anti-thyroid antibodies, rheumatoid factor, celiac antibodies as clinically indicated (oktay202518pdeletionsyndrome pages 1-2)

Imaging Studies: - Brain MRI: Recommended to evaluate for white matter anomalies, holoprosencephaly, pituitary abnormalities (66% have abnormal findings) (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 9-10) - Echocardiography: To screen for cardiac defects (56% affected) (hasi‐zogaj2015areviewof pages 7-8) - Ophthalmologic examination: For ptosis, strabismus, refractive errors, and rare retinal anomalies (hasi‐zogaj2015areviewof pages 7-8)

Functional Tests: - Audiology: Audiometry to assess for hearing loss (23% overall; conductive more common than sensorineural) (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11) - Developmental/Neuropsychological Assessment: Cognitive testing (average IQ 69, range 51-99), adaptive behavior assessment (hasi‐zogaj2015areviewof pages 2-4)

Clinical Criteria and Differential Diagnosis

There are no standardized clinical diagnostic criteria; diagnosis is confirmed by genetic testing. Differential diagnosis includes other microdeletion syndromes and isolated features such as holoprosencephaly from other causes, isolated growth hormone deficiency, and syndromic intellectual disability (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 11-12).

Screening

  • Newborn Screening: Not part of routine newborn screening panels
  • Prenatal Screening: May be detected incidentally on prenatal CMA performed for other indications; non-invasive prenatal testing (NIPT) may detect large deletions but is not a primary screening tool for 18p deletion (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3)
  • Carrier Screening: Relevant for families with balanced translocations; preimplantation genetic diagnosis theoretically possible (hasi‐zogaj2015areviewof pages 11-12)

11. Outcome/Prognosis

Survival and Mortality

  • Life Expectancy: Compatible with survival into adulthood; the condition was historically described as the "first reported partial monosomy compatible with life" (papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 1-2). Specific mortality data not provided in retrieved literature, but the syndrome is not considered lethal.
  • Mortality Rate: Not specifically documented; chronic condition with lifelong management needs

Morbidity and Function

  • Cognitive Function: Average full-scale IQ of 69 (range 51-99), typically falling in the mild to borderline intellectual disability range (hasi‐zogaj2015areviewof pages 2-4)
  • Adaptive Functioning: Majority have problems with activities of daily living including communication, home living, self-care, and social/leisure activities (hasi‐zogaj2015areviewof pages 2-4)
  • Autism Risk: 19-38% score in the clinically significant range on autism rating scales (hasi‐zogaj2015areviewof pages 9-10, hasi‐zogaj2015areviewof pages 8-9)
  • Medical Morbidity: Chronic medical complications including recurrent infections (otitis media 61%), cardiac disease (56%), endocrine dysfunction (23-13%), sensory impairments, and potential adult-onset conditions (FSHD2, autoimmunity, dystonia) (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 8-9, balog2018monosomy18pis pages 1-3)

Quality of Life

Problems with communication, self-care, home living, and social functioning significantly impact quality of life (hasi‐zogaj2015areviewof pages 2-4). Educational and vocational support needs are substantial for most individuals.

Disease Course and Complications

Common Complications: - Recurrent infections due to immunodeficiency (hasi‐zogaj2015areviewof pages 7-8) - Cardiac complications requiring surgical intervention (hasi‐zogaj2015areviewof pages 7-8) - Chronic otitis media leading to conductive hearing loss (hasi‐zogaj2015areviewof pages 7-8) - Endocrine deficiencies requiring hormone replacement (hasi‐zogaj2015areviewof pages 7-8) - Scoliosis/kyphosis potentially requiring bracing or surgery (hasi‐zogaj2015areviewof pages 10-11) - Adult-onset: dystonia, FSHD2 (if permissive background), autoimmune disease (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 8-9, balog2018monosomy18pis pages 1-3)

Recovery Potential: The chromosomal abnormality is permanent; symptomatic treatments can improve function (e.g., growth hormone therapy for GH deficiency, cardiac surgery, hearing aids), but the underlying genetic condition persists (hasi‐zogaj2015areviewof pages 7-8).

Prognostic Factors

  • Deletion size and specific genes involved (genotype-phenotype correlations) (hasi‐zogaj2015areviewof pages 2-4, hasi‐zogaj2015areviewof pages 11-12)
  • Early intervention and multidisciplinary management (hasi‐zogaj2015areviewof pages 11-12)
  • Presence of SMCHD1 deletion plus permissive 4q background (FSHD2 risk) (balog2018monosomy18pis pages 1-3)

12. Treatment

Pharmacotherapy

Supportive Medications: - Growth hormone therapy: For isolated growth hormone deficiency; individuals respond to treatment (hasi‐zogaj2015areviewof pages 7-8) - Thyroid hormone replacement: For hypothyroidism/hypopituitarism (hasi‐zogaj2015areviewof pages 7-8, oktay202518pdeletionsyndrome pages 1-2) - Immunoglobulin replacement: For significant immunoglobulin deficiency (hasi‐zogaj2015areviewof pages 7-8) - Antiepileptic drugs: For seizure management (13% affected) (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 10-11) - Immunosuppressive/disease-modifying agents: For autoimmune diseases as clinically indicated (oktay202518pdeletionsyndrome pages 1-2)

Pharmacogenomics: No specific pharmacogenomic considerations documented in retrieved literature.

Advanced Therapeutics

No gene therapy, cell therapy, RNA-based therapies, or targeted molecular therapies are currently available or under investigation for chromosome 18p deletion syndrome.

Surgical and Interventional

  • Cardiac surgery: For structural heart defects (e.g., VSD repair, tetralogy of Fallot correction) (hasi‐zogaj2015areviewof pages 7-8)
  • Orthopedic interventions: Bracing or surgical correction for scoliosis/kyphosis (hasi‐zogaj2015areviewof pages 10-11)
  • Ophthalmologic surgery: For strabismus, cataracts as needed (hasi‐zogaj2015areviewof pages 7-8)
  • Ear tube placement: For chronic otitis media (hasi‐zogaj2015areviewof pages 7-8)

Supportive and Rehabilitative

  • Early intervention services: Physical therapy, occupational therapy, speech therapy (hasi‐zogaj2015areviewof pages 11-12)
  • Developmental therapies: To optimize cognitive and adaptive functioning (hasi‐zogaj2015areviewof pages 2-4, hasi‐zogaj2015areviewof pages 11-12)
  • Educational support: Special education services, individualized education plans (hasi‐zogaj2015areviewof pages 2-4)
  • Audiologic/ophthalmologic management: Hearing aids, glasses, ongoing monitoring (hasi‐zogaj2015areviewof pages 7-8)
  • Nutritional support: For feeding difficulties in infancy (hasi‐zogaj2015areviewof pages 7-8)

Treatment Strategy and Algorithms

Recommended Anticipatory Guidance (from Hasi-Zogaj 2015): - At diagnosis: - Chromosomal microarray to define deletion breakpoints (hasi‐zogaj2015areviewof pages 11-12) - Parental karyotype to rule out balanced translocation (hasi‐zogaj2015areviewof pages 11-12) - Echocardiography to rule out cardiac defects (hasi‐zogaj2015areviewof pages 11-12) - Brain MRI to evaluate structural anomalies (hasi‐zogaj2015areviewof pages 11-12) - Pituitary function monitoring (growth, endocrine axes) (hasi‐zogaj2015areviewof pages 11-12) - Ophthalmology and audiology evaluations (hasi‐zogaj2015areviewof pages 11-12) - Immunoglobulin levels (hasi‐zogaj2015areviewof pages 11-12) - Referral to early intervention services (hasi‐zogaj2015areviewof pages 11-12) - Ongoing surveillance: - Endocrine monitoring (especially for growth hormone deficiency and thyroid function) - Regular ophthalmology/audiology follow-up - Monitoring for autoimmune disease manifestations - For individuals with SMCHD1 deletion: genetic testing for 4q D4Z4 permissive background and clinical monitoring for FSHD2 (balog2018monosomy18pis pages 1-3)

MAXO (Medical Action Ontology) Terms (suggested): - MAXO:0000004 (hormone replacement therapy) - MAXO:0000058 (developmental therapy) - MAXO:0000011 (surgical procedure) - MAXO:0001175 (rehabilitation therapy)

13. Prevention

Primary Prevention

  • Genetic counseling: For families with known balanced translocations; recurrence risk depends on the specific translocation (hasi‐zogaj2015areviewof pages 11-12)
  • Preimplantation genetic diagnosis (PGD): Theoretically possible for known familial rearrangements, though not specifically documented in retrieved literature

Secondary Prevention

  • Prenatal diagnosis: CMA on CVS or amniocentesis can detect 18p deletions, though prenatal phenotype prediction is challenging due to variable expressivity (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3)
  • Early multisystem screening: At diagnosis to identify cardiac, endocrine, ophthalmologic, audiologic, and immunologic issues for early intervention (hasi‐zogaj2015areviewof pages 11-12)

Tertiary Prevention

  • Treatment of complications: Growth hormone therapy, cardiac surgery, management of infections, seizure control, autoimmune disease treatment (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 11-12)
  • Surveillance for late-onset features: Monitoring for dystonia, FSHD2, autoimmune disease in at-risk individuals (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 8-9, balog2018monosomy18pis pages 1-3)

Screening Programs

  • Newborn screening: Not part of routine newborn screening
  • Cascade screening: Not applicable (predominantly de novo condition)

14. Other Species / Natural Disease

Natural Disease in Other Species

No naturally occurring chromosome 18p deletion syndrome has been described in other species in the retrieved literature.

15. Model Organisms

Gene-Specific Mouse Models

While no comprehensive mouse model of chromosome 18p deletion syndrome exists in the retrieved literature, several individual gene knockout/knockdown models have been studied:

TGIF1 Knockout Mice: Heterozygous TGIF1 knockout mice exposed prenatally to retinoic acid show significantly increased risk for facial deformities (30%), holoprosencephaly (23%), and neural tube defects (7%), recapitulating the HPE phenotype seen in human 18p deletion (hasi‐zogaj2015areviewof pages 9-10).

CETN1 Heterozygous Mice: Male mice with heterozygous CETN1 mutations are infertile, though this phenotype has not been confirmed in humans with 18p deletion (maternal transmission documented) (hasi‐zogaj2015areviewof pages 4-7).

AFG3L2 Models: Deletions and duplications of AFG3L2 in mice are associated with ataxia phenotypes, though point mutations are more penetrant than copy number changes (hasi‐zogaj2015areviewof pages 8-9, hasi‐zogaj2015areviewof pages 10-11).

LAMA1 Mutant Mice: Chemically induced mutations in LAMA1 result in retinal vasculopathy characterized by vitreous fibroplasia and vessel tortuosity (hasi‐zogaj2015areviewof pages 7-8).

TWSG1 Knockout Mice: Knockout mice show defects in craniofacial and dorsal-ventral patterning during embryonic development; prenatal retinoic acid exposure increases risk of malformations (hasi‐zogaj2015areviewof pages 9-10).

Model Applications

These gene-specific models are useful for understanding individual gene functions and testing potential therapeutic interventions, but do not fully recapitulate the complex multi-gene haploinsufficiency of human 18p deletion syndrome.

Summary and Conclusions

Chromosome 18p deletion syndrome (OMIM #146390) is a rare chromosomal disorder with an estimated prevalence of 1 in 50,000 live births, characterized by partial or complete monosomy of the short arm of chromosome 18 (papamichail2024prenataldiagnosisof pages 1-3, papamichail2023prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 1-2). The syndrome presents with highly variable clinical features including cognitive impairment (average IQ 69), minor dysmorphic features, hypotonia (84%), cardiac defects (56%), brain MRI anomalies (66%), and multisystem involvement (hasi‐zogaj2015areviewof pages 1-2, hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 2-4).

Approximately 89% of cases arise de novo, while ~11% are familial, often resulting from unbalanced translocations (hasi‐zogaj2015areviewof pages 2-4). Breakpoint location varies, with ~42% occurring in the centromeric region and the remainder scattered along the p arm, contributing to phenotypic heterogeneity (hasi‐zogaj2015areviewof pages 2-4). Current understanding identifies 12 dosage-sensitive genes out of 67 on 18p, with variable penetrance for specific phenotypes: TGIF1 (holoprosencephaly 11%), SMCHD1 (conditional FSHD2 risk), GNAL (dystonia 3%), PTPN2 (autoimmunity ~11%), and others (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 2-4, hasi‐zogaj2015areviewof pages 4-7, hasi‐zogaj2015areviewof pages 8-9).

Diagnosis relies on chromosomal microarray analysis for deletion detection and breakpoint mapping (papamichail2024prenataldiagnosisof pages 1-3, hasi‐zogaj2015areviewof pages 2-4). Parental karyotyping is recommended to identify balanced translocations (hasi‐zogaj2015areviewof pages 11-12). Management is primarily supportive and multidisciplinary, including early intervention, growth hormone therapy for GH deficiency, cardiac surgery for structural defects, and surveillance for late-onset complications (autoimmunity, dystonia, FSHD2) (hasi‐zogaj2015areviewof pages 7-8, hasi‐zogaj2015areviewof pages 11-12). Prognosis is compatible with survival into adulthood, though significant impacts on quality of life stem from cognitive impairment, medical comorbidities, and adaptive functioning challenges (hasi‐zogaj2015areviewof pages 2-4).

This comprehensive report synthesizes current evidence from primary literature to provide a foundation for disease knowledge base entry, clinical management, and future research into genotype-phenotype correlations and potential therapeutic targets.

References

  1. (papamichail2024prenataldiagnosisof pages 1-3): Maria Papamichail, Anna Eleftheriades, Emmanouil Manolakos, Adamantia Papamichail, Panagiotis Christopoulos, Gwendolin Manegold-Brauer, and Makarios Eleftheriades. Prenatal diagnosis of 18p deletion and 8p trisomy syndrome: literature review and report of a novel case. BMC Women's Health, Apr 2024. URL: https://doi.org/10.1186/s12905-024-03081-4, doi:10.1186/s12905-024-03081-4. This article has 1 citations.

  2. (papamichail2023prenataldiagnosisof pages 1-3): Maria Papamichail, Anna Eleftheriades, Emmanouil Manolakos, Adamantia Papamichail, Panagiotis Christopoulos, Gwendolin Manegold-Brauer, and Makarios Eleftheriades. Prenatal diagnosis of 18p deletion and 8p trisomy syndrome: case report and review of literature. Unknown journal, Nov 2023. URL: https://doi.org/10.21203/rs.3.rs-3405499/v1, doi:10.21203/rs.3.rs-3405499/v1.

  3. (hasi‐zogaj2015areviewof pages 1-2): Minire Hasi‐Zogaj, Courtney Sebold, Patricia Heard, Erika Carter, Bridgette Soileau, Annice Hill, David Rupert, Brian Perry, Sidney Atkinson, Louise O'Donnell, Jon Gelfond, Jack Lancaster, Peter T. Fox, Daniel E. Hale, and Jannine D. Cody. A review of 18p deletions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 169:251-264, Sep 2015. URL: https://doi.org/10.1002/ajmg.c.31445, doi:10.1002/ajmg.c.31445. This article has 93 citations.

  4. (hasi‐zogaj2015areviewof pages 7-8): Minire Hasi‐Zogaj, Courtney Sebold, Patricia Heard, Erika Carter, Bridgette Soileau, Annice Hill, David Rupert, Brian Perry, Sidney Atkinson, Louise O'Donnell, Jon Gelfond, Jack Lancaster, Peter T. Fox, Daniel E. Hale, and Jannine D. Cody. A review of 18p deletions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 169:251-264, Sep 2015. URL: https://doi.org/10.1002/ajmg.c.31445, doi:10.1002/ajmg.c.31445. This article has 93 citations.

  5. (oktay202518pdeletionsyndrome pages 1-2): Mehmet Ali Oktay, Elif Tuğçe Tunca Küçükali, Aylin Kılınç Uğurlu, Esra Döğer, Gülsüm Kayhan, Mahmut Orhun Çamurdan, and Aysun Bideci. 18p deletion syndrome associated with type 1 diabetes and hashimoto’s thyroiditis: a case report on autoimmune disorders and genetic factors. Journal of Clinical Research in Pediatric Endocrinology, Nov 2025. URL: https://doi.org/10.4274/jcrpe.galenos.2025.2025-6-5, doi:10.4274/jcrpe.galenos.2025.2025-6-5. This article has 1 citations.

  6. (hasi‐zogaj2015areviewof pages 2-4): Minire Hasi‐Zogaj, Courtney Sebold, Patricia Heard, Erika Carter, Bridgette Soileau, Annice Hill, David Rupert, Brian Perry, Sidney Atkinson, Louise O'Donnell, Jon Gelfond, Jack Lancaster, Peter T. Fox, Daniel E. Hale, and Jannine D. Cody. A review of 18p deletions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 169:251-264, Sep 2015. URL: https://doi.org/10.1002/ajmg.c.31445, doi:10.1002/ajmg.c.31445. This article has 93 citations.

  7. (hasi‐zogaj2015areviewof pages 4-7): Minire Hasi‐Zogaj, Courtney Sebold, Patricia Heard, Erika Carter, Bridgette Soileau, Annice Hill, David Rupert, Brian Perry, Sidney Atkinson, Louise O'Donnell, Jon Gelfond, Jack Lancaster, Peter T. Fox, Daniel E. Hale, and Jannine D. Cody. A review of 18p deletions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 169:251-264, Sep 2015. URL: https://doi.org/10.1002/ajmg.c.31445, doi:10.1002/ajmg.c.31445. This article has 93 citations.

  8. (hasi‐zogaj2015areviewof pages 11-12): Minire Hasi‐Zogaj, Courtney Sebold, Patricia Heard, Erika Carter, Bridgette Soileau, Annice Hill, David Rupert, Brian Perry, Sidney Atkinson, Louise O'Donnell, Jon Gelfond, Jack Lancaster, Peter T. Fox, Daniel E. Hale, and Jannine D. Cody. A review of 18p deletions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 169:251-264, Sep 2015. URL: https://doi.org/10.1002/ajmg.c.31445, doi:10.1002/ajmg.c.31445. This article has 93 citations.

  9. (hasi‐zogaj2015areviewof pages 8-9): Minire Hasi‐Zogaj, Courtney Sebold, Patricia Heard, Erika Carter, Bridgette Soileau, Annice Hill, David Rupert, Brian Perry, Sidney Atkinson, Louise O'Donnell, Jon Gelfond, Jack Lancaster, Peter T. Fox, Daniel E. Hale, and Jannine D. Cody. A review of 18p deletions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 169:251-264, Sep 2015. URL: https://doi.org/10.1002/ajmg.c.31445, doi:10.1002/ajmg.c.31445. This article has 93 citations.

  10. (balog2018monosomy18pis pages 1-3): Judit Balog, Remko Goossens, Richard J L F Lemmers, Kirsten R Straasheijm, Patrick J van der Vliet, Anita van den Heuvel, Chiara Cambieri, Nicolas Capet, Léonard Feasson, Veronique Manel, Julian Contet, Marjolein Kriek, Colleen M Donlin-Smith, Claudia A L Ruivenkamp, Patricia Heard, Stephen J Tapscott, Jannine D Cody, Rabi Tawil, Sabrina Sacconi, and Silvère M van der Maarel. Monosomy 18p is a risk factor for facioscapulohumeral dystrophy. Journal of Medical Genetics, 55:469-478, Mar 2018. URL: https://doi.org/10.1136/jmedgenet-2017-105153, doi:10.1136/jmedgenet-2017-105153. This article has 25 citations and is from a domain leading peer-reviewed journal.

  11. (hasi‐zogaj2015areviewof pages 10-11): Minire Hasi‐Zogaj, Courtney Sebold, Patricia Heard, Erika Carter, Bridgette Soileau, Annice Hill, David Rupert, Brian Perry, Sidney Atkinson, Louise O'Donnell, Jon Gelfond, Jack Lancaster, Peter T. Fox, Daniel E. Hale, and Jannine D. Cody. A review of 18p deletions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 169:251-264, Sep 2015. URL: https://doi.org/10.1002/ajmg.c.31445, doi:10.1002/ajmg.c.31445. This article has 93 citations.

  12. (hasi‐zogaj2015areviewof pages 9-10): Minire Hasi‐Zogaj, Courtney Sebold, Patricia Heard, Erika Carter, Bridgette Soileau, Annice Hill, David Rupert, Brian Perry, Sidney Atkinson, Louise O'Donnell, Jon Gelfond, Jack Lancaster, Peter T. Fox, Daniel E. Hale, and Jannine D. Cody. A review of 18p deletions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 169:251-264, Sep 2015. URL: https://doi.org/10.1002/ajmg.c.31445, doi:10.1002/ajmg.c.31445. This article has 93 citations.

Artifacts